Community/Retail

Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.

Biykem Bozkurt, MD, PhD, explains why survodutide's glucagon component called for a dedicated noninferiority trial in adults with obesity.

Brooke Hudspeth, PharmD, explains how pharmacists help patients link glucose trends to meals, activity, medications, and medication timing.

Optimal medical therapy scores, discharge prescribing, and readmissions data can help pharmacists demonstrate the value of heart failure services.

The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.

Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.

Cody Parsons, PharmD, APh, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.

The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.

Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.

Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.

Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.

Cody Parsons, PharmD, APh, BCCCP, explains how the AHA's 40-hospital collaborative is mapping care gaps for patients with HFpEF and HFmrEF.

Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.

RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.

ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.

The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.

Kristen Hartzell, PharmD, explains that long-term care pharmacies can counter vaccine fatigue and raise influenza vaccination rates among older adults.

Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.

A pharmacy technician reflects on 3 patient encounters that reshaped his understanding of what a real patient requires.

Brooke Hudspeth, PharmD, explains why community pharmacists, often the source of meters and supplies, are well positioned to guide new testers.

Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.

Pharmacists have shown they can safely do more for patients. Now regulation and reimbursement have to catch up.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.